This Week in TB R&D – 29 June 2010

28 Jun 2010
by Working Group

A biochip assay- an example of a diagnostic test based on disease biomarkers

By far, one of the greatest needs in TB R&D is the identification of biomarkers. The value of biomarkers cannot be overemphasized. Briefly, we will highlight what biomarkers are, how they are used, and describe their importance and potential for significant impact for TB drug discovery.

The term ‘biomarker’ refers to a biological indicator and serves as a marker of disease. A biomarker can derive from the host in response to a disease or infection, or directly from the pathogen or disease agent. Biomarkers are used for diagnosis, (you have TB), prognosis (how your body is responding to TB infection), stratification of TB (e.g. latent vs. active infection), or most important to drug discovery, a surrogate marker/endpoint.

A surrogate endpoint is an alternate datapoint that reflects the benefit of TB drug or vaccine treatment. Current TB trials are lengthy because patients must be followed for at least 2yr post treatment to determine if the patient’s TB has relapsed, which would indicate that the drug treatment was ineffective. A TB surrogate biomarker that is sensitive to whether a patient (host) is beginning to recover and/or the elimination or killing of the bacteria would significantly reduce costs of drug trials by decreasing the duration of the drug trial. For instance, patient A in a drug trial is expected to fully recover from infection (the bacteria is in the process of elimination or is completely killed) because patient A is showing a favorable change in ‘biomarker X’ and ‘biomarker X’ has been shown to be linked to elimination of the bacteria. Whereas, patient B is the same drug trial is not responding to treatment because ‘biomarker X’ from patient B is not responding appropriately. The key to the biomarker field is, first, their discovery, and second, their rigorous validation by showing that they robustly predict a relevant clinical effect (for example, cure).

Two recent publications by Parida and Kaufmann in Drug Discovery Today and Wallis and colleagues in The Lancet highlight the current status and progress in TB biomarker research. Using multiple ‘–omics’-based approaches (e.g. proteomics, metabolomics, etc.) the identification of more valuable biomarkers for TB active verses latent and infected verses cured will hopefully soon be realized.

What value would biomarkers add to basic research in general? What biomarkers are you currently investigating? Do you think a valid biomarker can be identified? What alternate approaches would you support? Please add your thoughts and comments below.

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...